Jazz Pharmaceuticals to Acquire Chimerix Today, March 5, 2025, Jazz Pharmaceuticals (JAZZ) and Chimerix (CMRX) announced the companies have entered into a definitive agreement for Jazz . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, cardiovascular disease, and Neuroscience, each representing a blockbuster opportunity – – Announces TRITON Phase 3 program for next-generation TTR silencer nucresiran in ATTR-CM and hATTR-PN, targeting durable franchise leadership – – Provides details about Phase 3 cardiovascular outcomes trial for zilebesiran, poised to transform the treatment of hypertension in patients with high CV risk – …
Sanofi A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi (SNY) and Johnson & Johnson’s (
Eledon Pharmaceuticals The patient was treated in the procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, and was recently released from the hospital. Today, February 07, 2025, Eledon Pharmaceuticals (ELDN) announced that tegoprubart, its investigational anti-CD40L antibody, was used as a key component of the immunosuppression therapy regimen in a patient who recently received . . . This content is …
Supernus Pharmaceuticals Supernus Pharmaceuticals (SUPN) - a biopharmaceutical company focused on developing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults . . . This content is for …
Halozyme Therapeutics Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing authorization for a subcutaneous (SC) formulation of RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for . . . This content is for paid subscribers. Please click here …
Akero Therapeutics Full Press Release Following our shortened report earlier today, this posting is from the Company’s information and its press release. The news demonstrated statistically significant compensated cirrhosis (F4) reversal due to MASH by Both Completer and ITT Analyses at Week 96 in Phase 2b SYMMETRY Study. Akero Therapeutics (AKRO), released preliminary topline week 96 results from SYMMETRY . . . This content is …
Akero Therapeutics Waiting to hear the news from Akero Therapeutics in treating NASH, the company reported Preliminary Topline Results showing statistically significant reversal of compensated Cirrhosis (F4) due to Mash-by both completer and ITT analyses- at week 96 in Phase 2b SYMMETRY Study. Indeed, Akero Therapeutics (
Vera Therapeutics in the Market Today Today, many investors in the biotechnology market caused a selloff of Vera Therapeutics (VERA) following its announcement of an exclusive license agreement with Stanford University to acquire a next generation fusion protein targeting BAFF and APRIL, known as VT-109. VT-109 has wide therapeutic potential across the spectrum of B cell mediated diseases. What Vera Therapeutics . . . This …
Compugen January 8, 2025, Compugen (CGEN), announced that the first patient was dosed in a Phase 1 clinical trial with COM503, a potential first-in-class antibody against IL-18 binding protein licensed by Compugen to Gilead. Compugen is responsible for running the Phase 1 trial. This Phase 1 multi-center dose escalation and dose expansion trial will evaluate the safety, tolerability . . . This content is for …
Halozyme Therapeutics Today, January 8, 2025 /PRNewswire/ - Halozyme Therapeutics, Inc. (HALO) provided a financial update, reiterating full year 2024 financial guidance and raising full year 2025 and multi-year financial guidance. The Company has also announced that. it has recently entered into . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Verona Pharma Today, January 7, 2024 Verona Pharma (VRNA) announced preliminary unaudited net product sales for the fourth quarter and full year ended December 31, 2024, and provides a corporate update. Let’s read what the Company’s President stated: David Zaccardelli, Pharm. D., President and Chief Executive Officer said,“2024 was another transformational year for Verona with the approval and US . . . This content is …
Novo Nordisk Bagsværd, Denmark, 12 December 2024 – Novo Nordisk (NVO) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly subcutaneous semaglutide) label to reflect data from the FLOW kidney outcomes trial. The FLOW trial assessed the risk reduction . . . This content is for paid …
Gilead Sciences Kite Pharma, a Gilead Sciences Company (GILD) announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta ® (axicabtagene ciloleucel) in patients with relapsed/refractory non-Hodgkin lymphomas (NHL), including follicular lymphoma (FL) or marginal zone . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Vertex Pharmaceuticals ASH Announcement Today, December 8, 2024, Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Keros Therapeutics in the NEWS Today, December 3, 2024, Keros Therapeutics (KROS) announced an exclusive global development and commercialization license agreement with Takeda (TAK) to advance elritercept. Elritercept is currently in two ongoing Phase 2 clinical trials: one in patients with very low-, low-, or intermediate-risk myelodysplastic syndrome (MDS) and one in patients with myelofibrosis (MF
PTC Therapeutics in the NEWS Today, December 2, 2024, PTC Therapeutics (PTCT) announced the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (
Biogen & UCB Announcement Today, November 19, 2024, UCB (Euronext Brussels: (UCB) and Biogen (BIIB) presented . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Adaptimmune Therapeutics Announcement Today, November 13, 2024, Adaptimmune Therapeutics plc (ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy announced data from the primary analysis of its pivotal Phase 2 IGNYTE-ESO trial of lete-cel in people with synovial sarcoma or the myxoid/round cell liposarcoma (MRCLS) who received previous anthracycline . . . This content is for paid subscribers. Please …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
